BioAtla, Inc. is a clinical-stage biopharmaceutical company developing conditionally active biologic (CAB) antibody-based therapeutics for solid tumor cancers. Its CAB technology exploits pH differences between tumor microenvironments and healthy tissue to selectively bind cancer cells, reducing toxicity. Lead candidates include ozuriftamab vedotin (BA3021), a CAB anti-ROR2 ADC, and BA3182, a CAB-EpCAM x CAB-CD3 bispecific antibody. As of March 2026, the company is exploring strategic options including asset sales and licensing.
Q2 FY2026 — expected 2026-09-14
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-03-31 | 2025-12-31 | 0001193125-26-134499 | EDGAR | 102K words |
| 2025-03-28 | 2024-12-31 | 0000950170-25-046217 | EDGAR | 92K words |
| 2024-03-26 | 2023-12-31 | 0000950170-24-036548 | EDGAR | 89K words |
| 2023-03-23 | 2022-12-31 | 0000950170-23-009551 | EDGAR | 94K words |
| 2022-02-28 | 2021-12-31 | 0000950170-22-002303 | EDGAR | — |
| 2021-03-24 | 2020-12-31 | 0001193125-21-092812 | EDGAR | — |
| Filed | Period | Accession | Source | Full Text |
|---|---|---|---|---|
| 2026-08-13 | 2026-06-30 | 0001193125-26-349542 | EDGAR | 68K words |
| 2025-11-13 | 2025-09-30 | 0001193125-25-280435 | EDGAR | 61K words |
| 2025-08-07 | 2025-06-30 | 0000950170-25-105220 | EDGAR | 60K words |
| 2025-05-06 | 2025-03-31 | 0000950170-25-064594 | EDGAR | 56K words |
| 2024-11-07 | 2024-09-30 | 0000950170-24-123506 | EDGAR | 57K words |
| 2024-08-08 | 2024-06-30 | 0000950170-24-094164 | EDGAR | 55K words |
| 2024-05-14 | 2024-03-31 | 0000950170-24-059757 | EDGAR | 52K words |
| 2023-11-07 | 2023-09-30 | 0000950170-23-060389 | EDGAR | 56K words |
| 2023-08-01 | 2023-06-30 | 0000950170-23-036554 | EDGAR | 56K words |
| 2023-05-11 | 2023-03-31 | 0000950170-23-021358 | EDGAR | 54K words |
| 2022-11-04 | 2022-09-30 | 0000950170-22-022036 | EDGAR | — |
| 2022-08-09 | 2022-06-30 | 0000950170-22-016149 | EDGAR | — |
| Filed | Accession | Source | Full Text |
|---|---|---|---|
| 2026-08-28 | 0001539497-26-002373 | EDGAR | 1K words |
| 2026-07-16 | 0001193125-26-306117 | EDGAR | 1K words |
| 2026-04-02 | 0001193125-26-140053 | EDGAR | 1K words |
| 2026-03-31 | 0001193125-26-134501 | EDGAR | 3K words |
| 2026-03-23 | 0001193125-26-119698 | EDGAR | 1K words |
| 2026-03-02 | 0001539497-26-000812 | EDGAR | 3K words |
| 2026-02-09 | 0001193125-26-041852 | EDGAR | 1K words |
| 2026-02-06 | 0001193125-26-041367 | EDGAR | 2K words |
| 2026-01-30 | 0001193125-26-031942 | EDGAR | 5K words |
| 2026-01-12 | 0001193125-26-010458 | EDGAR | 2K words |
103 total filings indexed. 75 additional filings (S-1, DEF 14A, etc.) View all (JSON) · SEC EDGAR
| CIK | 0001826892 |
| Ticker | BCAB |
| Exchange | Nasdaq |
| SIC | 2836: Biological Products, (No Diagnostic Substances) |
| Incorporated | DE |
| Website | https://www.bioatla.com |
| Listed | 2020-12-16 |
This is a static snapshot. For live, structured JSON with cryptographic provenance chain:
MCP (recommended for AI): claude mcp add origin --transport http https://origin.rootz.global/mcp
Try it — paste this into your AI:
Works in ChatGPT, Claude, Gemini, or any AI. Free, structured, cryptographically signed — ~500 tokens vs 130,000 scraping an IR site.
claude mcp add origin --transport http https://origin.rootz.global/mcpGET https://origin.rootz.global/api/company/BCAB (~200 tokens, structured JSON with cryptographic provenance)